Focused On-demand Library for Diacylglycerol O-acyltransferase 1

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O75907

UPID:
DGAT1_HUMAN

ALTERNATIVE NAMES:
ACAT-related gene product 1; Acyl-CoA retinol O-fatty-acyltransferase; Diglyceride acyltransferase

ALTERNATIVE UPACC:
O75907; B2RWQ2; D3DWL6; Q96BB8

BACKGROUND:
The enzyme Diacylglycerol O-acyltransferase 1, known for catalyzing the final step in triacylglycerol synthesis, is essential for dietary fat absorption in the small intestine and fat storage in the liver. It is also involved in producing milk fat in mammary glands and plays a role in skin and hair health by maintaining retinoid balance. DGAT1's activity is linked to the assembly of very low density lipoproteins.

THERAPEUTIC SIGNIFICANCE:
Given DGAT1's critical function in fat metabolism and its association with Diarrhea 7, protein-losing enteropathy type, targeting DGAT1 could offer novel therapeutic avenues. Understanding the role of Diacylglycerol O-acyltransferase 1 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.